Pharmacokinetics and dosage adjustment of rifabutin in a haemodialysis patient [13]

Nephrology Dialysis Transplantation

Volumn 17, Issue 3, 2002, Pages 531-532

  Bassilios, Nader ^a   Launay Vacher, Vincent ^a   Hamani, Abdel Aziz ^a   Masias, Laurent ^a   Peytavin, Gilles ^b   Fau, Jean Baptiste ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANSAMYCIN DERIVATIVE; CYCLOSPORIN A; ISONIAZID; PYRAZINAMIDE; RIFABUTIN; RIFAMYCIN DERIVATIVE; TUBERCULOSTATIC AGENT;

BACTERICIDAL ACTIVITY; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEART TRANSPLANTATION; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; LETTER; MYCOBACTERIOSIS; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0036194444     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/17.3.531-a     Document Type: Letter

References (5)

1. Identification of urinary metabolites of rifamycin LM 427 in man
2. Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man
3. Drug dose in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations
4. Clinical pharmacokinetics of rifabutin